Katja Klausz, Group Leader and Senior Scientist at University Medical Center Schleswig-Holstein, shared on LinkedIn:
“Such a great pleasure to be invited to present our work (Dorothee Winterberg, Suzanne Lentzsch) on novel anti-myeloma NK cell engagers in the Riney Session on September 25th at this year’s IMS26 annual meeting in Glasgow!
Thanks to the Paula & Roger Riney Foundation for supporting our preclinical work. The data I’ll present show the potential of NK cell-engaging molecules for myeloma therapy. I can’t wait to discuss them with experts from all over the world!”
You may also be interested in: Myeloma Paper of the Day, September 23rd, Suggested by Robert Orlowski
